These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

816 related items for PubMed ID: 12949282

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR.
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R, Wolfler A, Picone S, Rossi GA, Gualberti G, Merolla R, Del Vecchio A, Villani A, Midulla F, Dotta A.
    Ital J Pediatr; 2019 Nov 09; 45(1):139. PubMed ID: 31706338
    [Abstract] [Full Text] [Related]

  • 7. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic].
    Grupo de Hospitales Benazuza.
    An Esp Pediatr; 2002 Apr 09; 56(4):293-7. PubMed ID: 11927095
    [Abstract] [Full Text] [Related]

  • 8. Hospitalization for Respiratory Syncytial Virus Bronchiolitis in the Palivizumab Prophylaxis Era: Need for Reconsideration of Preventive Timing and Eligibility.
    Oz-Alcalay L, Ashkenazi S, Glatman-Freedman A, Weisman-Demri S, Lowenthal A, Livni G.
    Isr Med Assoc J; 2019 Feb 09; 21(2):110-115. PubMed ID: 30772962
    [Abstract] [Full Text] [Related]

  • 9. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA, Cosgrove JF, MacMahon P.
    Ir Med J; 2000 Dec 09; 93(9):284. PubMed ID: 11209917
    [Abstract] [Full Text] [Related]

  • 10. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
    Lanctôt KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI.
    Curr Med Res Opin; 2008 Nov 09; 24(11):3223-37. PubMed ID: 18928643
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
    Pediatrics; 1998 Nov 09; 102(5):1211-6. PubMed ID: 9794957
    [Abstract] [Full Text] [Related]

  • 14. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 09; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 15. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ.
    J Manag Care Pharm; 2010 Sep 09; 16(1):46-58. PubMed ID: 20131495
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
    Fitzgerald DA.
    Paediatr Respir Rev; 2009 Sep 09; 10(3):143-7. PubMed ID: 19651385
    [Abstract] [Full Text] [Related]

  • 18. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
    Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.
    Hum Vaccin Immunother; 2014 Sep 09; 10(10):2789-94. PubMed ID: 25483663
    [Abstract] [Full Text] [Related]

  • 19. Prophylaxis against respiratory syncytial virus in premature infants.
    Bont L, van Vught AJ, Kimpen JL.
    Lancet; 1999 Sep 18; 354(9183):1003-4. PubMed ID: 10501371
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
    Cetinkaya M, Oral TK, Karatekin S, Cebeci B, Babayigit A, Yesil Y.
    Eur J Clin Microbiol Infect Dis; 2017 Sep 18; 36(9):1629-1634. PubMed ID: 28391538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.